碧桂園(02007.HK):去年累計交付近70萬套房
碧桂園(02007.HK)於微信公眾號公布,2022年集團累計交付近70萬套房屋。
於1月6日,碧桂園集團召開2023年首次月度管理會議,以「起跑即衝刺,開戰即決戰」的狀態做好當下工作,打好2023年「翻身之戰」。集團主席楊國強表示,於美國、澳洲、香港等城鎮化率較高的地方,房地產市場依然紅火,相信中國房地產行業也會實現平穩健康發展。
碧桂園日前披露未經審核營運數據顯示,去年全年,歸屬股東權益的合同銷售金額3,574.7億元人民幣(下同);權益合同銷售建築面積4,450.3萬平方米。去年12月單月歸屬股東權益的合同銷售金額約220.3億元,權益合同銷售建築面積約282萬平方米。(ta/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.